Drug Database
Back to search

Finland· FI-REL-REL57956

VYDURA

A rimegepant product containing rimegepant sulfate, registered in Finland by Pfizer Europe MA EEIG. The same ATC class is registered in 16 of our 19 countries.

ATC N02CD06

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedVYDURAATCN02CD06REGISTER NO.FI-REL-REL57956PACKS LISTED0CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about rimegepant sulfateAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Rimegepant is registered in 16 of 19 countries.

Countries holding a registration under ATC N02CD06 (rimegepant), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 11 of them publish a price we can compare per daily dose
Search rimegepant products by name

Rimegepant · ATC N02CD06

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rimegepant costs, country by country.

Normalised to the WHO defined daily dose (37.5 mg), the median price runs from $14.84 in Switzerland to $64.33 in United States — a ×4.3 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail
Open the full comparison — free accountDrug prices for market access

Rimegepant · price per daily dose (37.5 mg)

USD · FX 28 Sept 2026

  • US United States$64.33 (acquisition cost)
  • IT Italy$18.89
  • ES Spain$16.29
  • CH Switzerland$14.84
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

Fimea (Finland)
Active substance
Rimegepant sulfate
Manufacturer
Pfizer Europe MA EEIG
Country
Finland (FI)
ATC code
N02CD06
ATC class
Rimegepant
Defined daily dose
37.5 mg, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

90 interactions on record for rimegepant.

Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check rimegepant against other medicinesHow interaction checks work

Rimegepant · interactions on record

90 records

  • 9 severe
  • 81 moderate

Most severe, free to view

  • DexamethasoneH02AB02severe
  • DabrafenibL01EC02severe
  • LorlatinibL01ED05severe
  • DabrafenibL01XE23severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rimegepant in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rimegepant products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Vydura
  • Liechtenstein · Vydura
  • Norway · Vydura

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/dd56c9b0-d3bf-4bdc-a853-c800b3556921
GET /v1/drugs/dd56c9b0-d3bf-4bdc-a853-c800b3556921?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "37.5",
  "form": "tabletti, kylmäkuivattu",
  "route": "Suun kautta",
  "ddd_unit": "mg",
  "strength": "75 mg",
  "atc_label": "rimegepantti",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/22/1645/001-003",
  "fimea_rel_id": "REL57956",
  "authorised_at": "2022-04-25"
}
API referenceMCP serverPlans

See everything about rimegepant.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console